Who is sponsoring NCT01648699?

NCT01648699 is sponsored by Janssen Pharmaceutica.

What drugs are being tested in NCT01648699?

Interventions: Osmotic Release Oral System (OROS) hydromorphone.

What is the status of NCT01648699?

NCT01648699 is currently TERMINATED.

Last reviewed 2013-10-01 · How we verify

Study on the Effectiveness and Safety of OROS Hydromorphone in Pain Management Among Patients With Cancer Pain

NCT01648699 Phase 4 TERMINATED Results posted

The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorphone using standardized conversion from prior opioid therapy among participants with cancer pain.

Details

Lead sponsor	Janssen Pharmaceutica
Phase	Phase 4
Status	TERMINATED
Enrolment	20
Start date	2010-04
Completion	2010-09

Conditions

Pain

Interventions

Osmotic Release Oral System (OROS) hydromorphone

Primary outcomes

Brief Pain Inventory (BPI) Average Score at Baseline — Baseline
The Brief Pain Inventory (BPI) assesses the severity of pain and the impact of pain on daily functions (interference items). The severity items are scored from 0=no pain and 10=pain as bad as you can imagine. The interference items are scored from 0=no interference and 10=interferes completely.
Brief Pain Inventory (BPI) Average Score at Day 28 — Day 28
The BPI assesses the severity of pain and the impact of pain on daily functions (interference items). The severity items are scored from 0=no pain and 10=pain as bad as you can imagine. The interference items are scored from 0=no interference and 10=interferes completely.